You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Exosomes Market Research Report 2019-2027

Exosomes are extracellular lipid nanovesicles of 30 nm to 120 nm diameter. These are secreted by different cells and are found in all bodily fluids such as urine, plasma, saliva, serum, and cerebrospinal fluid (CSF). Release of exosomes takes place either upon induction or constitutively, under both pathological and normal conditions, in a regulated, dynamic, and functionally relevant manner. Exosomes are separated from diverse cell lines such as tumor lines, primary cultures, hematopoietic cells, virus infected cells, and also from biological fluids in blood, including plasma and serum from cancer patients and other body fluids such as pleural effusions, broncho alveolar lavage fluid, amniotic fluid, synovial fluid, semen, saliva, and urine. Exosomes have pleiotropic physiological and pathological functions. These play vital role in various pathological conditions such as infectious, cancer, and neurodegenerative diseases.

According to the World Health Organization, globally, cancer is considered to be the second leading cause of death, and it accounted for nearly 9.6 million deaths in 2018. Globally, cancer accounts for around 1 in 6 deaths. The impact of cancer economically is significant and is rising. In 2010, the total annual economic cost of cancer was anticipated at around US$ 1.16 Trn. Rise in prevalence of cancer, increase in funds for life science research, surge in research programs which focus on the determination of the role of exosomes, and increase in interest in exosome-based procedures are the factors boosting the growth of the global exosome research products market. However, shortage of skilled and trained personnel is a major factor likely to hamper the growth of the global exosome research products market during the forecast period.

The global exosome research products market can be segmented based on product & service, application, and end-user. In terms of product & service, the market can be classified into kits & reagents, instruments, and services. The kits & reagents segment is anticipated to account for the largest market share during the forecast period. Based on application, the global exosome research products market can be bifurcated into cancer and non-cancer. The cancer segment can be categorized into colorectal cancer, breast cancer, lung cancer, prostate cancer, and other cancers. The lung cancer sub-segment is projected to account for the largest share of the cancer segment from 2019 to 2027. In terms of end-user, the market can be divided into hospitals & clinical testing laboratories, academic & research institutes, and pharmaceutical & biotechnology companies. The academic & research institutes segment is expected to account for the largest market share during the forecast period.

In terms of region, the global exosome research products market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the global exosome research products market from 2019 to 2027. This is attributed to favorable regulatory environment, rise in focus and interest in exosome research and diagnostics, and government funding for research on life sciences. Additionally, growth of the pharmaceutical & biotechnology industries and presence of well-built and high-quality infrastructure for laboratory and clinical research drive the market in North America. The market in Asia Pacific is projected to grow at a rapid pace during the forecast period due to rise in research and developmental activities, increase in government initiatives for improving health care, and surge in focus of key players in building or strengthening presence in the region.

Key players in the global exosome research products market include Thermo Fisher Scientific, Bio-Techne, QIAGEN, System Biosciences, LLC, Miltenyi Biotec, NanoSomiX, Norgen Biotek Corp., AMS Biotechnology (Europe) Limited, Lonza, and Novus Biologicals. These players have adopted strategies such as partnerships, agreements, new product development, and collaborations to gain competitive advantage in the global exosome research products market.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. DIAGNOSTIC IS THE MAJORLY USED APPLICATION
3.2.2. SOFTWARE SEGMENT IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
3.2.3. CANCER INSTITUTES HOLD THE LARGEST MARKET SHARE IN TERMS OF END-USER

4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. INCREASE IN PERVASIVENESS OF CANCER
4.2.2. RISING GOVERNMENT AND NON GOVERNMENT INITIATIVES
4.2.3. ADVANCEMENT IN TECHNOLOGY
4.3. MARKET RESTRAINTS
4.3.1. CHALLENGES FACED IN THE USAGE OF EXOSOME
4.3.2. STRINGENT REGULATION
4.4. MARKET OPPORTUNITIES
4.4.1. LUCRATIVE GROWTH OPPORTUNITIES IN THE EMERGING ECONOMIES
4.4.2. INCREASE IN ADOPTION OF INNOVATIVE AND ADVANCED EXOSOME DIAGNOSTIC AND THERAPEUTIC PROCEDURES
4.5. MARKET CHALLENGES
4.5.1. LOW AWARENESS IN THE DEVELOPING COUNTRIES

5. MARKET BY APPLICATION
5.1. DIAGNOSTIC
5.2. THERAPEUTIC

6. MARKET BY PRODUCT
6.1. INSTRUMENT
6.2. REAGENT
6.3. SOFTWARE

7. MARKET BY END-USER
7.1. CANCER INSTITUTE
7.2. HOSPITAL
7.3. DIAGNOSTIC CENTER
7.4. OTHER END-USER

8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCES MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF BUYERS
8.1.4. BARGAINING POWER OF SUPPLIERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. EXOSOME ETYMOLOGY
8.3. PATENT ANALYSIS
8.4. COMPONENTS OF EXOSOME
8.5. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. THE UNITED STATES
9.1.2. CANADA
9.2. EUROPE
9.2.1. GERMANY
9.2.2. FRANCE
9.2.3. THE UNITED KINGDOM
9.2.4. ITALY
9.2.5. SPAIN
9.2.6. REST OF EUROPE
9.3. ASIA PACIFIC
9.3.1. JAPAN
9.3.2. CHINA
9.3.3. INDIA
9.3.4. AUSTRALIA
9.3.5. SOUTH KOREA
9.3.6. REST OF ASIA PACIFIC
9.4. REST OF WORLD
9.4.1. LATIN AMERICA
9.4.2. MIDDLE EAST AND AFRICA

10. COMPETITIVE LANDSCAPE
10.1. COMPANY PROFILES
10.1.1. AETHLON MEDICAL, INC.
10.1.2. BIOCAT GMBH
10.1.3. CAPRICOR THERAPEUTICS, INC.
10.1.4. CODIAK BIOSCIENCES
10.1.5. EVOX THERAPEUTICS LTD.
10.1.6. EXOSOME DIAGNOSTICS INC.
10.1.7. HANSABIOMED LIFE SCIENCES LTD. (ACQUIRED BY LONZA)
10.1.8. HITACHI CHEMICAL DIAGNOSTICS, INC.
10.1.9. MALVERN INSTRUMENTS LTD.
10.1.10. MBL INTERNATIONAL CORPORATION
10.1.11. NANOSOMIX INC.
10.1.12. SISTEMIC LTD.
10.1.13. SYSTEM BIOSCIENCES (SBI)
10.1.14. THERMO FISHER SCIENTIFIC INC.
10.1.15. QIAGEN N.V.
  • FORMAT: PDF
  • PUBLISHED DATE: Dec, 2019
  • NO OF PAGES: 125